COMPASS Pathways (CMPS) Stock Soars 25% on Trump’s Psychedelics Research Order

Key Takeaways

• An executive order from President Trump aims to expedite psychedelic therapy research and patient access for PTSD and severe mental health conditions.
• Shares of COMPASS Pathways (CMPS) climbed 25% in premarket hours after the announcement.
• The company disclosed encouraging results from two Phase 3 studies evaluating COMP360 synthetic psilocybin for depression that resists conventional treatment.
• A rolling submission to the FDA for COMP360 approval is currently in progress.
• Wall Street firms including Oppenheimer, Jefferies, and RBC issued bullish commentary, highlighting expedited commercialization opportunities.

On April 20, 2026, President Trump issued an executive order instructing federal departments to fast-track research initiatives and broaden patient access to psychedelic compounds utilized internationally for treating PTSD and severe psychiatric disorders.

The announcement triggered substantial gains across psychedelic biotechnology stocks during premarket hours.

COMPASS Pathways (CMPS) topped the sector’s performance with a 25% surge. AtaiBeckley (ATAI) climbed 22%, Definium Therapeutics (DFTX) advanced 20%, while GH Research (GHRS) and Cybin (HELP) each posted 17% gains.

COMPASS Pathways plc, CMPS

The timing of the presidential directive coincided with significant clinical progress for COMPASS.

Earlier in April, the biotechnology firm announced successful outcomes from two Phase 3 clinical studies evaluating COMP360, its synthetic psilocybin candidate designed to address treatment-resistant depression (TRD). The company has initiated a rolling regulatory submission with the FDA.

COMP360 previously demonstrated encouraging efficacy and safety profiles in advanced-stage clinical trials. The rolling submission strategy allows regulatory reviewers to evaluate completed portions before receiving the complete application package — an approach that can reduce overall assessment timelines.

Wall Street Endorses Sector Outlook

Jay Olson from Oppenheimer characterized the executive order as “a structural inflection for the US psychedelics sector by facilitating research, regulatory timelines, and patient access.” Olson identified Atai Beckley, COMPASS Pathways, and Definium Therapeutics as companies possessing “differentiating advantages.”

Andrew Tsai at Jefferies noted coordination throughout the executive branch — encompassing Trump, HHS, FDA, and the VA — stating “investor mindshare should rise meaningfully ahead of potential approvals in 2027–30.” He emphasized that “the path to commercialization could be even faster now.”

Brian Abrahams from RBC described the order as catalyzing psychedelics as “the key next wave of mental health treatments,” identifying Definium Therapeutics, COMPASS Pathways, and GH Research as primary beneficiaries.

Financial Projections and Outlook

Wall Street projections for COMPASS demonstrate considerable variation. Bullish estimates anticipate revenues reaching $193.1 million with earnings of $24.2 million by 2029. Conservative forecasts suggest approximately $59.5 million in revenue and $6.5 million in earnings for the same period.

This substantial range underscores genuine uncertainty regarding regulatory label specifications, insurance reimbursement frameworks, and treatment facility infrastructure development.

COMPASS continues operating with negative cash flow, necessitating successful commercialization within a defined timeframe to prevent additional equity dilution or capital raises.

The company’s near-term catalysts include FDA evaluation of COMP360 for TRD, plus a prospective regulatory filing for PTSD treatment.

By April 20, 2026, CMPS stock had extended gains beyond 40% as regular trading commenced, building on the premarket momentum.

The post COMPASS Pathways (CMPS) Stock Soars 25% on Trump’s Psychedelics Research Order appeared first on Blockonomi.